The stock of Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) is a huge mover today! The stock last traded at $3.13 per share. It is down 4.68% since April 22, 2016 and is uptrending. It has underperformed by 0.73% the S&P500.
The move comes after 6 months positive chart setup for the $121.43M company. It was reported on Nov, 25 by Barchart.com. We have $3.35 PT which if reached, will make NASDAQ:AUPH worth $8.50M more.
Analysts await Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) to report earnings on March, 17. They expect $-0.11 earnings per share, up 31.25% or $0.05 from last year’s $-0.16 per share. After $-0.19 actual earnings per share reported by Aurinia Pharmaceuticals Inc for the previous quarter, Wall Street now forecasts -42.11% EPS growth.
According to Zacks Investment Research, “Aurinia Pharmaceuticals Inc. is a late stage biopharmaceutical company. It focuses on the development of therapeutic immunomodulating drug candidate. The company’s lead drug includes Voclosporin for the treatment of lupus nephritis. Aurinia Pharmaceuticals Inc. is headquartered in Victoria, Canada.”
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.